CHMP grants Novartis's Afinitor a positive opinion for advanced kidney cancer
This article was originally published in Scrip
Executive Summary
Novartis's Afinitor (everolimus) has received an EU CHMP positive opinion for the treatment of advanced renal cell carcinoma in patients whose disease has progressed during or after treatment with VEGF-targeted therapy.